Inhibitor Therapeutics Stock

Inhibitor Therapeutics, Inc. operates as a pharmaceutical development company that focuses on developing and ultimately commercializing innovative therapeutics for patients with certain cancers and certain non-cancerous proliferation disorders.

The company has explored and expects to continue to explore acquiring or licensing other innovative preclinical and clinical stage therapeutics addressing unmet needs and orphan indications beyond cancer.

The company's primary focus is on the development of therapies initially for prostate and lung cancer in the U.S. market utilizing itraconazole, a drug approved by the U.S. Food and Drug Administration (FDA) for, and has been extensively used to, treat fungal infections, and has an extensive history of safe and effective use in humans. The company has developed, optioned, and licensed intellectual property and know-how related to the treatment of cancer patients using itraconazole and certain itraconazole analogues.

Strategy

The key elements of the company's strategy are to seek FDA programs to expedite drug approvals and commercialize and market with exclusivity.

Research and Development

For the year ended December 31, 2022, the company's research and development expenses were $6,150.

History

The company was founded in 1992. It was incorporated in 2013. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in 2019.